Title:
THERAPEUTIC AGENT FOR BREAST CANCER
Document Type and Number:
WIPO Patent Application WO/2017/104739
Kind Code:
A1
Abstract:
The present application discloses a therapeutic agent for breast cancer, which comprises 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4- yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N- methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof.
More Like This:
Inventors:
MIYANO SAORI (JP)
YAMAMOTO YUJI (JP)
NAKAGAWA TAKAYUKI (JP)
YAMAMOTO YUJI (JP)
NAKAGAWA TAKAYUKI (JP)
Application Number:
PCT/JP2016/087349
Publication Date:
June 22, 2017
Filing Date:
December 15, 2016
Export Citation:
Assignee:
EISAI R&D MAN CO LTD (JP)
International Classes:
A61K31/4545; A61P15/00; A61P35/00
Foreign References:
| JP2014237707A | 2014-12-18 | |||
| JP5925978B1 | 2016-05-25 | |||
| US20140235614A1 | 2014-08-21 |
Other References:
ANDRE, F. ET AL.: "Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer", CLIN. CANCER RES., vol. 19, no. 13, 1 July 2013 (2013-07-01), pages 3693 - 3702, XP055138336, DOI: doi:10.1158/1078-0432.CCR-13-0190
KOZICZAK, M. ET AL.: "Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins", ONCOGENE, vol. 23, 2004, pages 3501 - 3508, XP055598820
DEY, J. H. ET AL.: "Targeting Fibroblast Growth Factor Receptors Blocks PI3K/AKT Signaling, Induces Apoptosis, and Impairs Mammary Tumor Outgrowth and Metastasis", CANCER RES., vol. 70, no. 10, 15 May 2010 (2010-05-15), pages 4151 - 4162, XP055031363, DOI: doi:10.1158/0008-5472.CAN-09-4479
TURNER, N. ET AL.: "FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer", CANCER RES., vol. 70, no. 5, 1 March 2010 (2010-03-01), pages 2085 - 2094, XP055031367, DOI: doi:10.1158/0008-5472.CAN-09-3746
BERRADA, N. ET AL.: "Treatment of triple- negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization?", ANNALS OF ONCOLOGY, vol. 21, no. 7, 2010, pages vii30 - vii35, XP009146071, DOI: doi:10.1093/annonc/mdq279
MIYANO, S. W. ET AL.: "E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models", MOL. CANCER THER., vol. 15, no. 11, November 2016 (2016-11-01), pages 2630 - 2639, XP055497036, DOI: doi:10.1158/1535-7163.MCT-16-0261
FOULKES ET AL.: "Triple-Negative Breast Cancer", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 363, 2010, pages 1938 - 1948
KOZICZAK ET AL.: "Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins", ONCOGENE, vol. 23, 2004, pages 3501 - 3508
"Japanese pharmacopoeia. 16th ed.", 2011, PHARMACEUTICAL AND MEDICAL DEVICE REGULATORY
KOZICZAK, M. ET AL.: "Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins", ONCOGENE, vol. 23, 2004, pages 3501 - 3508, XP055598820
DEY, J. H. ET AL.: "Targeting Fibroblast Growth Factor Receptors Blocks PI3K/AKT Signaling, Induces Apoptosis, and Impairs Mammary Tumor Outgrowth and Metastasis", CANCER RES., vol. 70, no. 10, 15 May 2010 (2010-05-15), pages 4151 - 4162, XP055031363, DOI: doi:10.1158/0008-5472.CAN-09-4479
TURNER, N. ET AL.: "FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer", CANCER RES., vol. 70, no. 5, 1 March 2010 (2010-03-01), pages 2085 - 2094, XP055031367, DOI: doi:10.1158/0008-5472.CAN-09-3746
BERRADA, N. ET AL.: "Treatment of triple- negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization?", ANNALS OF ONCOLOGY, vol. 21, no. 7, 2010, pages vii30 - vii35, XP009146071, DOI: doi:10.1093/annonc/mdq279
MIYANO, S. W. ET AL.: "E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models", MOL. CANCER THER., vol. 15, no. 11, November 2016 (2016-11-01), pages 2630 - 2639, XP055497036, DOI: doi:10.1158/1535-7163.MCT-16-0261
FOULKES ET AL.: "Triple-Negative Breast Cancer", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 363, 2010, pages 1938 - 1948
KOZICZAK ET AL.: "Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins", ONCOGENE, vol. 23, 2004, pages 3501 - 3508
"Japanese pharmacopoeia. 16th ed.", 2011, PHARMACEUTICAL AND MEDICAL DEVICE REGULATORY
Attorney, Agent or Firm:
HASEGAWA Yoshiki et al. (JP)
Download PDF: